Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

New class of rilmenidine analogues with high selectivity for I1 receptors and hypotensive activity

May 4, 2001

Pfizer identifies and characterizes potent and selective NHE-1 inhibitor

May 3, 2001

Oral endothelin receptor antagonist achieves primary endpoint in phase III trial for PAH

May 3, 2001

New endothelin receptor antagonists useful for circulatory disorders

April 30, 2001

Vasogen plans trial of immune modulation therapy for PAD

April 30, 2001

Icos initiates phase III trial of Pafase for treatment of severe sepsis

April 27, 2001

Merck KGaA presents new PDE5 inhibitors and their uses

April 26, 2001

Medicure successfully completes phase I trial of MC-1; phase II studies planned

April 20, 2001

Veletri fails to meet primary efficacy objective in RITZ-1

April 20, 2001

Inhibitors of sPLA2 described in recent patent literature by Shionogi

April 19, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
GABA signaling linked to immune resistance in some tumors
BioWorld
Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...